Jackson Gibbs

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Genes & Molecular Sequences

Living Beings

Concepts & Ideas

Physiology

Protein Prenylation

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Lutterbach Bart; Zeng Qinwen; Davis Lenora J; Hatch Harold; Hang Gaozhen; Kohl Nancy E; Gibbs Jackson B; Pan Bo-Sheng
Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival.
Sisko John T; Tucker Thomas J; Bilodeau Mark T; Buser Carolyn A; Ciecko Patrice A; Coll Kathleen E; Fernandes Christine; Gibbs Jackson B; Koester Timothy J; Kohl Nancy; Lynch Joseph J; Mao Xianzhi; McLoughlin Debra; Miller-Stein Cynthia M; Rodman Leonard D; Rickert Keith W; Sepp-Lorenzino Laura; Shipman Jennifer M; Thomas Kenneth A; Wong Bradley K; Hartman George D
Potent 2-[(pyrimidin-4-yl)amine}-1,3-thiazole-5-carbonitrile-based inhibitors of VEGFR-2 (KDR) kinase.
Bilodeau Mark T; Balitza Adrienne E; Koester Timothy J; Manley Peter J; Rodman Leonard D; Buser-Doepner Carolyn; Coll Kathleen E; Fernandes Christine; Gibbs Jackson B; Heimbrook David C; Huckle William R; Kohl Nancy; Lynch Joseph J; Mao Xianzhi; McFall Rosemary C; McLoughlin Debra; Miller-Stein Cynthia M; Rickert Keith W; Sepp-Lorenzino Laura; Shipman Jennifer M; Subramanian Raju; Thomas Kenneth A; Wong Bradley K; Yu Sean; Hartman George D
Potent N-(1,3-thiazol-2-yl)pyridin-2-amine vascular endothelial growth factor receptor tyrosine kinase inhibitors with excellent pharmacokinetics and low affinity for the hERG ion channel.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Jackson Gibbs (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2007: Lutterbach Bart; Zeng Qinwen; Davis Lenora J; Hatch Harold; Hang Gaozhen; Kohl Nancy E; Gibbs Jackson B; Pan Bo-Sheng
Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival.
Cancer research 2007;67(5):2081-8.
2006: Sisko John T; Tucker Thomas J; Bilodeau Mark T; Buser Carolyn A; Ciecko Patrice A; Coll Kathleen E; Fernandes Christine; Gibbs Jackson B; Koester Timothy J; Kohl Nancy; Lynch Joseph J; Mao Xianzhi; McLoughlin Debra; Miller-Stein Cynthia M; Rodman Leonard D; Rickert Keith W; Sepp-Lorenzino Laura; Shipman Jennifer M; Thomas Kenneth A; Wong Bradley K; Hartman George D
Potent 2-[(pyrimidin-4-yl)amine}-1,3-thiazole-5-carbonitrile-based inhibitors of VEGFR-2 (KDR) kinase.
Bioorganic & medicinal chemistry letters 2006;16(5):1146-50.
2004: Bilodeau Mark T; Balitza Adrienne E; Koester Timothy J; Manley Peter J; Rodman Leonard D; Buser-Doepner Carolyn; Coll Kathleen E; Fernandes Christine; Gibbs Jackson B; Heimbrook David C; Huckle William R; Kohl Nancy; Lynch Joseph J; Mao Xianzhi; McFall Rosemary C; McLoughlin Debra; Miller-Stein Cynthia M; Rickert Keith W; Sepp-Lorenzino Laura; Shipman Jennifer M; Subramanian Raju; Thomas Kenneth A; Wong Bradley K; Yu Sean; Hartman George D
Potent N-(1,3-thiazol-2-yl)pyridin-2-amine vascular endothelial growth factor receptor tyrosine kinase inhibitors with excellent pharmacokinetics and low affinity for the hERG ion channel.
Journal of medicinal chemistry 2004;47(25):6363-72.
2002: Tucker Thomas J; Abrams Marc T; Buser Carolyn A; Davide Joseph P; Ellis-Hutchings Michelle; Fernandes Christine; Gibbs Jackson B; Graham Samuel L; Hartman George D; Huber Hans E; Liu Dongming; Lobell Robert B; Lumma William C; Robinson Ronald G; Sisko John T; Smith Anthony M
The synthesis and biological evaluation of a series of potent dual inhibitors of farnesyl and geranyl-Geranyl protein transferases.
Bioorganic & medicinal chemistry letters 2002;12(15):2027-30.
2001: Bell I M; Gallicchio S N; Abrams M; Beshore D C; Buser C A; Culberson J C; Davide J; Ellis-Hutchings M; Fernandes C; Gibbs J B; Graham S L; Hartman G D; Heimbrook D C; Homnick C F; Huff J R; Kassahun K; Koblan K S; Kohl N E; Lobell R B; Lynch J J; Miller P A; Omer C A; Rodrigues A D; Walsh E S; Williams T M
Design and biological activity of (S)-4-(5-([1-(3-chlorobenzyl)-2-oxopyrrolidin-3-ylamino]methyl)imidazol-1-ylmethyl)benzonitrile, a 3-aminopyrrolidinone farnesyltransferase inhibitor with excellent cell potency.
Journal of medicinal chemistry 2001;44(18):2933-49.
2001: Dinsmore C J; Bergman J M; Wei D D; Zartman C B; Davide J P; Greenberg I B; Liu D; O'Neill T J; Gibbs J B; Koblan K S; Kohl N E; Lobell R B; Chen I W; McLoughlin D A; Olah T V; Graham S L; Hartman G D; Williams T M
Oxo-piperazine derivatives of N-arylpiperazinones as inhibitors of farnesyltransferase.
Bioorganic & medicinal chemistry letters 2001;11(4):537-40.
2000: Cohen-Jonathan E; Muschel R J; Gillies McKenna W; Evans S M; Cerniglia G; Mick R; Kusewitt D; Sebti S M; Hamilton A D; Oliff A; Kohl N; Gibbs J B; Bernhard E J
Farnesyltransferase inhibitors potentiate the antitumor effect of radiation on a human tumor xenograft expressing activated HRAS.
Radiation research 2000;154(2):125-32.
2000: Omer C A; Chen Z; Diehl R E; Conner M W; Chen H Y; Trumbauer M E; Gopal-Truter S; Seeburger G; Bhimnathwala H; Abrams M T; Davide J P; Ellis M S; Gibbs J B; Greenberg I; Koblan K S; Kral A M; Liu D; Lobell R B; Miller P J; Mosser S D; O'Neill T J; Rands E; Schaber M D; Senderak E T; Oliff A; Kohl N E
Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor.
Cancer research 2000;60(10):2680-8.
2000: Gibbs J B
Mechanism-based target identification and drug discovery in cancer research.
Science (New York, N.Y.) 2000;287(5460):1969-73.
2000: Gibbs J B
Anticancer drug targets: growth factors and growth factor signaling.
The Journal of clinical investigation 2000;105(1):9-13.
1999: Dinsmore C J; Williams T M; O'Neill T J; Liu D; Rands E; Culberson J C; Lobell R B; Koblan K S; Kohl N E; Gibbs J B; Oliff A I; Graham S L; Hartman G D
Imidazole-containing diarylether and diarylsulfone inhibitors of farnesyl-protein transferase.
Bioorganic & medicinal chemistry letters 1999;9(23):3301-6.
1999: Mahgoub N; Taylor B R; Gratiot M; Kohl N E; Gibbs J B; Jacks T; Shannon K M
In vitro and in vivo effects of a farnesyltransferase inhibitor on Nf1-deficient hematopoietic cells.
Blood 1999;94(7):2469-76.
1999: Anthony N J; Gomez R P; Schaber M D; Mosser S D; Hamilton K A; O'Neil T J; Koblan K S; Graham S L; Hartman G D; Shah D; Rands E; Kohl N E; Gibbs J B; Oliff A I
Design and in vivo analysis of potent non-thiol inhibitors of farnesyl protein transferase.
Journal of medicinal chemistry 1999;42(17):3356-68.
1999: Ciccarone T M; MacTough S C; Williams T M; Dinsmore C J; O'Neill T J; Shah D; Culberson J C; Koblan K S; Kohl N E; Gibbs J B; Oliff A I; Graham S L; Hartman G D
Non-thiol 3-aminomethylbenzamide inhibitors of farnesyl-protein transferase.
Bioorganic & medicinal chemistry letters 1999;9(14):1991-6.
1998: Lingham R B; Silverman K C; Jayasuriya H; Kim B M; Amo S E; Wilson F R; Rew D J; Schaber M D; Bergstrom J D; Koblan K S; Graham S L; Kohl N E; Gibbs J B; Singh S B
Clavaric acid and steroidal analogues as Ras- and FPP-directed inhibitors of human farnesyl-protein transferase.
Journal of medicinal chemistry 1998;41(23):4492-501.
1998: deSolms S J; Giuliani E A; Graham S L; Koblan K S; Kohl N E; Mosser S D; Oliff A I; Pompliano D L; Rands E; Scholz T H; Wiscount C M; Gibbs J B; Smith R L
N-Arylalkyl pseudopeptide inhibitors of farnesyltransferase.
Journal of medicinal chemistry 1998;41(14):2651-6.
1998: Mangues R; Corral T; Kohl N E; Symmans W F; Lu S; Malumbres M; Gibbs J B; Oliff A; Pellicer A
Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice.
Cancer research 1998;58(6):1253-9.
1998: Barrington R E; Subler M A; Rands E; Omer C A; Miller P J; Hundley J E; Koester S K; Troyer D A; Bearss D J; Conner M W; Gibbs J B; Hamilton K; Koblan K S; Mosser S D; O'Neill T J; Schaber M D; Senderak E T; Windle J J; Oliff A; Kohl N E
A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis.
Molecular and cellular biology 1998;18(1):85-92.
1998: Kohl N E; Koblan K S; Omer C A; Oliff A; Gibbs J B
Biochemical and biological analyses of farnesyl-protein transferase inhibitors.
Methods in molecular biology (Clifton, N.J.) 1998;84():283-91.
1997: Gibbs J B; Graham S L; Hartman G D; Koblan K S; Kohl N E; Omer C A; Oliff A
Farnesyltransferase inhibitors versus Ras inhibitors.
Current opinion in chemical biology 1997;1(2):197-203.
1997: Tang Y; Chen Z; Ambrose D; Liu J; Gibbs J B; Chernoff J; Field J
Kinase-deficient Pak1 mutants inhibit Ras transformation of Rat-1 fibroblasts.
Molecular and cellular biology 1997;17(8):4454-64.
1997: Omer C A; Anthony N J; Buser-Doepner C A; Burkhardt A L; deSolms S J; Dinsmore C J; Gibbs J B; Hartman G D; Koblan K S; Lobell R B; Oliff A; Williams T M; Kohl N E
Farnesyl: proteintransferase inhibitors as agents to inhibit tumor growth.
BioFactors (Oxford, England) 1997;6(3):359-66.
1997: Gibbs J B; Oliff A
The potential of farnesyltransferase inhibitors as cancer chemotherapeutics.
Annual review of pharmacology and toxicology 1997;37():143-66.
1996: Wallace A; Koblan K S; Hamilton K; Marquis-Omer D J; Miller P J; Mosser S D; Omer C A; Schaber M D; Cortese R; Oliff A; Gibbs J B; Pessi A
Selection of potent inhibitors of farnesyl-protein transferase from a synthetic tetrapeptide combinatorial library.
The Journal of biological chemistry 1996;271(49):31306-11.
1996: Oliff A; Gibbs J B; McCormick F
New molecular targets for cancer therapy.
Scientific American 1996;275(3):144-9.
1996: Koblan K S; Kohl N E; Omer C A; Anthony N J; Conner M W; deSolms S J; Williams T M; Graham S L; Hartman G D; Oliff A; Gibbs J B
Farnesyltransferase inhibitors: a new class of cancer chemotherapeutics.
Biochemical Society transactions 1996;24(3):688-92.
1996: Williams T M; Ciccarone T M; MacTough S C; Bock R L; Conner M W; Davide J P; Hamilton K; Koblan K S; Kohl N E; Kral A M; Mosser S D; Omer C A; Pompliano D L; Rands E; Schaber M D; Shah D; Wilson F R; Gibbs J B; Graham S L; Hartman G D; Oliff A I; Smith R L
2-substituted piperazines as constrained amino acids. Application to the synthesis of potent, non carboxylic acid inhibitors of farnesyltransferase.
Journal of medicinal chemistry 1996;39(7):1345-8.
1996: Gibbs J B; Kohl N E; Koblan K S; Omer C A; Sepp-Lorenzino L; Rosen N; Anthony N J; Conner M W; deSolms S J; Williams T M; Graham S L; Hartman G D; Oliff A
Farnesyltransferase inhibitors and anti-Ras therapy.
Breast cancer research and treatment 1996;38(1):75-83.
1995: Sepp-Lorenzino L; Ma Z; Rands E; Kohl N E; Gibbs J B; Oliff A; Rosen N
A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines.
Cancer research 1995;55(22):5302-9.
1995: Koblan K S; Schaber M D; Edwards G; Gibbs J B; Pompliano D L
src-homology 2 (SH2) domain ligation as an allosteric regulator: modulation of phosphoinositide-specific phospholipase C gamma 1 structure and activity.
The Biochemical journal 1995;305 ( Pt 3)():745-51.
1995: Kohl N E; Conner M W; Gibbs J B; Graham S L; Hartman G D; Oliff A
Development of inhibitors of protein farnesylation as potential chemotherapeutic agents.
Journal of cellular biochemistry. Supplement 1995;22():145-50.
1995: Kohl N E; Wilson F R; Thomas T J; Bock R L; Mosser S D; Oliff A; Gibbs J B
Inhibition of Ras function in vitro and in vivo using inhibitors of farnesyl-protein transferase.
Methods in enzymology 1995;255():378-86.
1995: Schaber M D; Gibbs J B
Determination of Ras and GTPase-activating protein interactions by kinetic competition assay.
Methods in enzymology 1995;255():171-8.
1995: Gibbs J B
Determination of guanine nucleotides bound to Ras in mammalian cells.
Methods in enzymology 1995;255():118-25.
1994: Gibbs J B; Oliff A
Pharmaceutical research in molecular oncology.
Cell 1994;79(2):193-8.
1994: Wai J S; Bamberger D L; Fisher T E; Graham S L; Smith R L; Gibbs J B; Mosser S D; Oliff A I; Pompliano D L; Rands E
Synthesis and biological activity of ras farnesyl protein transferase inhibitors. Tetrapeptide analogs with amino methyl and carbon linkages.
Bioorganic & medicinal chemistry 1994;2(9):939-47.
1994: Prendergast G C; Davide J P; deSolms S J; Giuliani E A; Graham S L; Gibbs J B; Oliff A; Kohl N E
Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton.
Molecular and cellular biology 1994;14(6):4193-202.
1994: Gibbs J B; Oliff A; Kohl N E
Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic.
Cell 1994;77(2):175-8.
1994: Prendergast G C; Gibbs J B
Ras regulatory interactions: novel targets for anti-cancer intervention?
BioEssays : news and reviews in molecular, cellular and developmental biology 1994;16(3):187-91.
1994: Zhang F L; Diehl R E; Kohl N E; Gibbs J B; Giros B; Casey P J; Omer C A
cDNA cloning and expression of rat and human protein geranylgeranyltransferase type-I.
The Journal of biological chemistry 1994;269(5):3175-80.
1994: Omer C A; Gibbs J B
Protein prenylation in eukaryotic microorganisms: genetics, biology and biochemistry.
Molecular microbiology 1994;11(2):219-25.
1993: Prendergast G C; Davide J P; Kral A; Diehl R; Gibbs J B; Omer C A; Kohl N E
Negative growth selection against rodent fibroblasts targeted for genetic inhibition of farnesyl transferase.
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1993;4(9):707-13.
1993: Pompliano D L; Schaber M D; Mosser S D; Omer C A; Shafer J A; Gibbs J B
Isoprenoid diphosphate utilization by recombinant human farnesyl:protein transferase: interactive binding between substrates and a preferred kinetic pathway.
Biochemistry 1993;32(32):8341-7.
1993: Kohl N E; Mosser S D; deSolms S J; Giuliani E A; Pompliano D L; Graham S L; Smith R L; Scolnick E M; Oliff A; Gibbs J B
Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor.
Science (New York, N.Y.) 1993;260(5116):1934-7.
1993: Omer C A; Kral A M; Diehl R E; Prendergast G C; Powers S; Allen C M; Gibbs J B; Kohl N E
Characterization of recombinant human farnesyl-protein transferase: cloning, expression, farnesyl diphosphate binding, and functional homology with yeast prenyl-protein transferases.
Biochemistry 1993;32(19):5167-76.
1993: Gibbs J B; Pompliano D L; Mosser S D; Rands E; Lingham R B; Singh S B; Scolnick E M; Kohl N E; Oliff A
Selective inhibition of farnesyl-protein transferase blocks ras processing in vivo.
The Journal of biological chemistry 1993;268(11):7617-20.
1993: Prendergast G C; Gibbs J B
Pathways of Ras function: connections to the actin cytoskeleton.
Advances in cancer research 1993;62():19-64.
1992: Gibbs J B
Pharmacological probes of Ras function.
Seminars in cancer biology 1992;3(6):383-90.
1992: Pompliano D L; Rands E; Schaber M D; Mosser S D; Anthony N J; Gibbs J B
Steady-state kinetic mechanism of Ras farnesyl:protein transferase.
Biochemistry 1992;31(15):3800-7.
1991: Stacey D W; Roudebush M; Day R; Mosser S D; Gibbs J B; Feig L A
Dominant inhibitory Ras mutants demonstrate the requirement for Ras activity in the action of tyrosine kinase oncogenes.
Oncogene 1991;6(12):2297-304.
1991: Stacey D W; Feig L A; Gibbs J B
Dominant inhibitory Ras mutants selectively inhibit the activity of either cellular or oncogenic Ras.
Molecular and cellular biology 1991;11(8):4053-64.
1991: Marshall M S; Davis L J; Keys R D; Mosser S D; Hill W S; Scolnick E M; Gibbs J B
Identification of amino acid residues required for Ras p21 target activation.
Molecular and cellular biology 1991;11(8):3997-4004.
1991: Moores S L; Schaber M D; Mosser S D; Rands E; O'Hara M B; Garsky V M; Marshall M S; Pompliano D L; Gibbs J B
Sequence dependence of protein isoprenylation.
The Journal of biological chemistry 1991;266(22):14603-10.
1991: Tsai M H; Roudebush M; Dobrowolski S; Yu C L; Gibbs J B; Stacey D W
Ras GTPase-activating protein physically associates with mitogenically active phospholipids.
Molecular and cellular biology 1991;11(5):2785-93.
1991: Gibbs J B
Ras C-terminal processing enzymes--new drug targets?
Cell 1991;65(1):1-4.
1991: Farnsworth C L; Marshall M S; Gibbs J B; Stacey D W; Feig L A
Preferential inhibition of the oncogenic form of RasH by mutations in the GAP binding/"effector" domain.
Cell 1991;64(3):625-33.
1990: Gibbs J B; Marshall M S; Scolnick E M; Dixon R A; Vogel U S
Modulation of guanine nucleotides bound to Ras in NIH3T3 cells by oncogenes, growth factors, and the GTPase activating protein (GAP).
The Journal of biological chemistry 1990;265(33):20437-42.
1990: Schaber M D; O'Hara M B; Garsky V M; Mosser S C; Bergstrom J D; Moores S L; Marshall M S; Friedman P A; Dixon R A; Gibbs J B
Polyisoprenylation of Ras in vitro by a farnesyl-protein transferase.
The Journal of biological chemistry 1990;265(25):14701-4.
1990: Gibbs J B
Toward the function of Ras: filling in the GAPs.
Cancer cells (Cold Spring Harbor, N.Y. : 1989) 1990;2(8-9):291-3.
1990: Hata Y; Kikuchi A; Sasaki T; Schaber M D; Gibbs J B; Takai Y
Inhibition of the ras p21 GTPase-activating protein-stimulated GTPase activity of c-Ha-ras p21 by smg p21 having the same putative effector domain as ras p21s.
The Journal of biological chemistry 1990;265(13):7104-7.
1990: Gibbs J B; Schaber M D; Garsky V M; Vogel U S; Scolnick E M; Dixon R A; Marshall M S
Structure/function relationships of ras and guanosine triphosphatase-activating protein.
Society of General Physiologists series 1990;45():77-85.
1989: Gibbs J B; Schaber M D; Schofield T L; Scolnick E M; Sigal I S
Xenopus oocyte germinal-vesicle breakdown induced by [Val12]Ras is inhibited by a cytosol-localized Ras mutant.
Proceedings of the National Academy of Sciences of the United States of America 1989;86(17):6630-4.
1989: Sigal I S; Gibbs J B
Oncogenes.
Current opinion in cell biology 1989;1(2):286-90.
1989: Marshall M S; Hill W S; Ng A S; Vogel U S; Schaber M D; Scolnick E M; Dixon R A; Sigal I S; Gibbs J B
A C-terminal domain of GAP is sufficient to stimulate ras p21 GTPase activity.
The EMBO journal 1989;8(4):1105-10.
1989: Schaber M D; Garsky V M; Boylan D; Hill W S; Scolnick E M; Marshall M S; Sigal I S; Gibbs J B
Ras interaction with the GTPase-activating protein (GAP).
Proteins 1989;6(3):306-15.
1988: Vogel U S; Dixon R A; Schaber M D; Diehl R E; Marshall M S; Scolnick E M; Sigal I S; Gibbs J B
Cloning of bovine GAP and its interaction with oncogenic ras p21.
Nature 1988;335(6185):90-3.
1988: Gibbs J B; Schaber M D; Allard W J; Sigal I S; Scolnick E M
Purification of ras GTPase activating protein from bovine brain.
Proceedings of the National Academy of Sciences of the United States of America 1988;85(14):5026-30.
1988: Marshall M S; Gibbs J B; Scolnick E M; Sigal I S
An adenylate cyclase from Saccharomyces cerevisiae that is stimulated by RAS proteins with effector mutations.
Molecular and cellular biology 1988;8(1):52-61.
1988: Sigal I S; Marshall M S; Schaber M D; Vogel U S; Scolnick E M; Gibbs J B
Structure/function studies of the ras protein.
Cold Spring Harbor symposia on quantitative biology 1988;53 Pt 2():863-9.
1988: Sigal I S; D'Alonzo J S; Ahern J D; Marshall M S; Smith G M; Scolnick E M; Gibbs J B
The ras oncogene protein as a G-protein.
Advances in second messenger and phosphoprotein research 1988;21():193-200.
1987: Sigal I S; Smith G M; Jurnak F; Marsico-Ahern J D; D'Alonzo J S; Scolnick E M; Gibbs J B
Molecular approaches towards an anti-ras drug.
Anti-cancer drug design 1987;2(2):107-15.
1987: Gibbs J B; Schaber M D; Marshall M S; Scolnick E M; Sigal I S
Identification of guanine nucleotides bound to ras-encoded proteins in growing yeast cells.
The Journal of biological chemistry 1987;262(22):10426-9.
1987: Marshall M S; Gibbs J B; Scolnick E M; Sigal I S
Regulatory function of the Saccharomyces cerevisiae RAS C-terminus.
Molecular and cellular biology 1987;7(7):2309-15.
1987: Robinson L C; Gibbs J B; Marshall M S; Sigal I S; Tatchell K
CDC25: a component of the RAS-adenylate cyclase pathway in Saccharomyces cerevisiae.
Science (New York, N.Y.) 1987;235(4793):1218-21.
1986: Sigal I S; Gibbs J B; D'Alonzo J S; Scolnick E M
Identification of effector residues and a neutralizing epitope of Ha-ras-encoded p21.
Proceedings of the National Academy of Sciences of the United States of America 1986;83(13):4725-9.
1986: Sigal I S; Gibbs J B; D'Alonzo J S; Temeles G L; Wolanski B S; Socher S H; Scolnick E M
Mutant ras-encoded proteins with altered nucleotide binding exert dominant biological effects.
Proceedings of the National Academy of Sciences of the United States of America 1986;83(4):952-6.
1985: Temeles G L; Gibbs J B; D'Alonzo J S; Sigal I S; Scolnick E M
Yeast and mammalian ras proteins have conserved biochemical properties.
Nature 1985;313(6004):700-3.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Jackson Gibbs

Research Profile (preview)

Chemicals & Drugs

Genes & Molecular Sequences

Living Beings

Concepts & Ideas

Physiology

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Jackson Gibbs (preview)

All Publications